This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Nov. 4, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, will announce financial results for the third quarter ended
September 30, 2013, on
Tuesday, November 12, 2013 prior to market open. The announcement will be followed by a live webcast and conference call at
8:30 a.m. Eastern time (
5:30 a.m. Pacific time).
Orexigen management will host the call and webcast to discuss financial results and recent business highlights. The live call may be accessed by phone by calling (888) 895-5479 (domestic) or (847) 619-6250 (international), participant code 36014873.
The following day, Orexigen management will present a company overview at the Credit Suisse Healthcare Conference in
Scottsdale, Arizona. The presentation is scheduled for
Wednesday, November 13th at
9:30 a.m. Mountain Time.
The webcasts of the live and subsequently archived conference call and conference presentation can be accessed on the Investor Relations section of the Orexigen web site at
www.orexigen.com and will be archived for 14 days following each event.
About Orexigen Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave®, which has completed Phase III clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the Contrave cardiovascular outcomes trial. The Company's other product candidate, Empatic™, has completed Phase II clinical trials. Further information about the Company can be found at
McDavid Stilwell Vice President, Corporate Communications & Business Development 858-875-8600
SOURCE Orexigen Therapeutics, Inc.